P37.5 Neonatal candidiasis

Name of the Condition

• Neonatal candidiasis (ICD-10-CM Code: P37.5)

Summary

Neonatal candidiasis is a fungal infection in newborns caused by Candida species, typically acquired during or shortly after birth. The infection can manifest in various forms, including mucocutaneous, invasive, or systemic disease, with severity depending on the infant's immune status and gestational age.

Causes

The infection is caused by Candida species, most commonly Candida albicans. Transmission occurs through vertical exposure during delivery (e.g., maternal vaginal colonization) or postnatal contact with contaminated surfaces, equipment, or caregivers. Invasive disease may result from skin barrier disruption or immunocompromise.

Risk Factors

• Prematurity (especially very low birth weight infants)
• Use of broad-spectrum antibiotics or corticosteroids
• Central venous catheters or invasive medical devices
• Maternal vaginal Candida colonization at delivery
• Immunocompromised status (e.g., congenital immune deficiencies)

Symptoms

Symptoms vary by infection type: mucocutaneous disease may present with oral thrush, diaper rash, or skin lesions; invasive disease can cause respiratory distress, feeding intolerance, or organ dysfunction. Systemic candidiasis may involve sepsis-like signs, including hypotension or organ failure.

Diagnosis

Diagnosis relies on clinical evaluation and laboratory testing. Cultures (blood, urine, or lesion swabs) confirm Candida presence. Imaging (e.g., echocardiography for endocarditis) or biomarkers (e.g., β-D-glucan) may support invasive disease. Differential diagnosis excludes bacterial sepsis or other fungal infections.

Treatment Options

Treatment depends on infection severity: mucocutaneous cases may use topical antifungals (e.g., nystatin); invasive disease requires systemic therapy (e.g., fluconazole, amphotericin B). Duration and agent selection consider renal function, species susceptibility, and clinical response.

Prognosis and Follow-Up

Prognosis is favorable for localized disease but worsens with systemic involvement, especially in preterm infants. Follow-up includes monitoring for recurrence, organ dysfunction, or treatment-related toxicity. Long-term outcomes depend on infection extent and underlying risk factors.

Complications

Complications include persistent infection, organ damage (e.g., renal, cardiac), or treatment failure. Preterm infants face higher risks of mortality or neurodevelopmental impairment with invasive disease. Rarely, chronic mucocutaneous candidiasis may develop.

Lifestyle & Prevention

Preventive measures include antifungal prophylaxis in high-risk preterm infants, strict hygiene practices (e.g., handwashing), and avoiding unnecessary antibiotic use. Maternal screening and treatment for vaginal candidiasis before delivery may reduce transmission risk.

When to Seek Professional Help

Seek care if symptoms worsen (e.g., fever, lethargy, poor feeding) or fail to improve with treatment. Immediate evaluation is critical for suspected systemic infection, especially in preterm or immunocompromised infants.

Tips for Medical Coders

Code P37.5 is assigned for neonatal candidiasis, including localized or systemic disease. Document the infection site (e.g., mucocutaneous, invasive) and any underlying risk factors (e.g., prematurity) to support code specificity. Differentiate from other fungal or bacterial infections to ensure accurate coding.